Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation

British Journal of Haematology

Volumn 157, Issue 3, 2012, Pages 407-410

  Coude, Marie Magdelaine ^a   Luycx, Odile ^b   Cariou, Marie Estelle ^b   Maarek, Odile ^a   Dombret, Hervé ^c   Cayuela, Jean Michel ^a   Rea, Delphine ^c  

^a Laboratoire Central d'Hematologie   (France)

^b Centre Hospitalier de Bretagne Sud   (France)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

CML BCR ABL1; Leukaemia therapy; Mutations

Indexed keywords

BCR ABL PROTEIN; HOMOHARRINGTONINE; IMATINIB; NILOTINIB;

AGED; BCR ABL1 GENE; CANCER RELAPSE; CASE REPORT; CHROMOSOME DUPLICATION; CHRONIC MYELOID LEUKEMIA; CYTOPENIA; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GENE DOSAGE; GENE MUTATION; HEMATOLOGIC DISEASE; HUMAN; LETTER; MEDICAL DECISION MAKING; MINIMAL RESIDUAL DISEASE; ONCOGENE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE; FEMALE; HARRINGTONINES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; NEOPLASM, RESIDUAL; PIPERAZINES; PYRIMIDINES;

EID: 84859483944     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.09016.x     Document Type: Letter

References (9)

1. Cortes, J., Talpaz, M., Bixby, D., Deininger, M., Shah, N., Flinn, I.W., Mauro, M., O'Hare, T., Hu, S., Kan, R., Rivera, V.M., Clackson, T., Haluska, F. & Kantarjian, H. (2010) A phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings. Blood (ASH Annual Meeting Abstracts), 116, abstract [210].
2. Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N. & Sawyers, C.L. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 293, 876-880.
3. Lavallade, H., Khorashad, J.S., Davis, H.P., Milojkovic, D., Kaeda, J.S., Goldman, J.M., Apperley, J.A. & Marin, D. (2007) Interferon-α or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. Blood, 110, 2779-2780.
4. T315I transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge? Leukemia, 21, 2204-2206.
5. Marin, D., Kaeda, J.S., Andreasson, C., Saunders, S.M., Bua, M., Olavarria, E., Goldman, J.M. & Apperley, J.F. (2005) Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer, 103, 1850-1855.
6. Nanda, N., Cortes, J., Lipton, J., Rea, D., Digumarti, R., Chuah, C., Benichou, A.C., Craig, A., Michallet, M. & Nicolini, F. (2011) Treatment of chronic phase (CP) chronic myeloid leukaemia (CML) patients who harbour the BCR-ABL T315I mutation with subcutaneous omacetaxine results in improved survival compared to historical data. Haematologica, 96, S2; abstract [1012].
7. Nicolini, F.E., Chomel, J.C., Roy, L., Legros, L., Chabane, K., Ducastelle, S., Nicolas-Virelizier, E., Michallet, M., Tigaud, I., Magaud, J.P., Turhan, A., Guilhot, F. & Hayette, S. (2010) The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge. Clinical Lymphoma, Myeloma and Leukemia, 10, 394-399.
8. Shah, N.P., Tran, C., Lee, F.Y., Chen, P., Norris, D. & Sawyers, C.L. (2004) Overriding imatinib resistance with a novel ABL inhibitor. Science, 305, 399-401.
9. Weisberg, E., Manley, P.W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S.W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., Kung, A.L., Mestan, J., Daley, G.Q., Callahan, L., Catley, L., Cavazza, C., Azam, M., Neuberg, D., Wright, R.D., Gilliland, D.G. & Griffin, J.D. (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell, 7, 129-141.